Weisberg Ilan S, Jacobson Ira M
Division of Gastroenterology and Hepatology, Department of Medicine, Center for the Study of Hepatitis C, Weill Cornell Medical College, New York Presbyterian Hospital, NY 10021, USA.
Clin Liver Dis. 2009 Aug;13(3):441-52. doi: 10.1016/j.cld.2009.05.009.
Standard therapy with pegylated interferon and ribavirin for chronic hepatitis C is effective in 40% to 50% of individuals with genotype 1 hepatitis C virus (HCV) infection and is associated with significant treatment-related toxicities. Newly developed small molecules that target key enzymes essential for HCV replication are in development. Telaprevir, a peptidomimetic inhibitor of the HCV NS3/4A protease, has shown great promise in early trials and is currently in advanced stages of clinical development. In treatment-naïve patients and those with previous treatment failure, the addition of telaprevir to standard interferon and ribavirin therapy is well tolerated and enhances rates of sustained virologic response while shortening the treatment duration. In this report, the current experience using telaprevir to treat chronic HCV infection as monotherapy and in combination with other agents is reviewed.
聚乙二醇化干扰素和利巴韦林用于慢性丙型肝炎的标准疗法，对40%至50%的基因型1丙型肝炎病毒（HCV）感染者有效，但会引发显著的治疗相关毒性。新研发的靶向HCV复制所必需关键酶的小分子药物正在研发中。替拉韦啶是一种HCV NS3/4A蛋白酶的拟肽抑制剂，在早期试验中已显示出巨大潜力，目前正处于临床研发的后期阶段。在未经治疗的患者以及先前治疗失败的患者中，将替拉韦啶添加到标准干扰素和利巴韦林疗法中耐受性良好，可提高持续病毒学应答率，同时缩短治疗疗程。在本报告中，回顾了目前使用替拉韦啶单药治疗及与其他药物联合治疗慢性HCV感染的经验。
